ES2627019T3 - Medios y procedimientos para diagnosticar y vigilar la insuficiencia cardiaca en un sujeto - Google Patents

Medios y procedimientos para diagnosticar y vigilar la insuficiencia cardiaca en un sujeto Download PDF

Info

Publication number
ES2627019T3
ES2627019T3 ES12745444.5T ES12745444T ES2627019T3 ES 2627019 T3 ES2627019 T3 ES 2627019T3 ES 12745444 T ES12745444 T ES 12745444T ES 2627019 T3 ES2627019 T3 ES 2627019T3
Authority
ES
Spain
Prior art keywords
until
acid
positive
sphingomyelin
tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12745444.5T
Other languages
English (en)
Inventor
Regina Reszka
Jens Fuhrmann
Jürgen KASTLER
Bianca Bethan
Martin Kluttig
Hugo Katus
Norbert Frey
Johanna Wolf
Tanja Weis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Heidelberg
BASF Metabolome Solutions GmbH
Original Assignee
Universitaet Heidelberg
Metanomics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Heidelberg, Metanomics GmbH filed Critical Universitaet Heidelberg
Application granted granted Critical
Publication of ES2627019T3 publication Critical patent/ES2627019T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/30—Control of physical parameters of the fluid carrier of temperature
    • G01N2030/3076—Control of physical parameters of the fluid carrier of temperature using specially adapted T(t) profile
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8665—Signal analysis for calibrating the measuring apparatus
    • G01N30/8668—Signal analysis for calibrating the measuring apparatus using retention times
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/146666—Bile pigment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • Y10T436/148888—Uric acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/171538—Urea or blood urea nitrogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/203332—Hydroxyl containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/21—Hydrocarbon

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Un procedimiento para diagnosticar la insuficiencia cardiaca en un sujeto, que comprende las etapas de: a) determinar, en una muestra de un sujeto que se sospecha que padece insuficiencia cardiaca, la cantidad de al menos un biomarcador seleccionado entre los biomarcadores relacionados en la Tabla 1A1, 1A2, 1B1, 1B2, 2A1, 2A2, 2B1, 2B2, 3A1, 3A2, 3B1, 3B2, 4A1, 4A2, 4B1, 4B2, 5A1, 5A2, 5B1, 5B2, 6A1, 6A2, 6B1, 6B2, 7A1, 7A2, 7B1, 7B2, 8A1, 8A2, 8B1 o 8B2; en el que uno de dicho al menos un biomarcador es colesterilester C18:0; b) comparar la cantidad de dicho al menos un biomarcador con una referencia, mediante lo cual se va a diagnosticar la insuficiencia cardiaca.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
Tabla 2A.2: Metabolitos que están significativamente disminuidos en plasma (valor p < 0,05) entre pacientes de CHF (DCMP) asintomáticos con NYHA I y controles
METABOLITO Biliverdina eritro-C16-Esfingosina treo-Esfingosina (*1) 5-O-Metilesfiingosina (*1) CE-Colesterilester C16:0
relación
regulación valor p
0,562
hasta 0,027
0,8592
hasta 0,029152
0,8906
hasta 0,013527
0,8943
hasta 0,047886
0,9077
hasta 0,043609
Tabla 3A.1: Metabolitos que están significativamente aumentados en plasma (valor p < 0,05) entre pacientes de CHF (ICMP) asintomáticos con NYHA I y controles
METABOLITO Ácido 4-Hidroxi-3-metoximandélico TAG (C16:0,C18:1,C18:2) TAG (C18:1,C18:2) TAG (C16:O,C16:1) TAG (C18:2,C18:2) ácido 15-hidroxieicosatetraenoico (C20:cis[5,8,11,13]4) TAG (C18:2,C18:3) TAG (C16:0,C18:1,C18:3) ácido 8-hidroxieicosatetraenoico (C20:[5] trans[9,11,14]4) (8-HETE) Ácido 14,15-Dihidroxieicosatrienoico (C20:cis[5,8,11]3) DAG (C18:1,C18:2) Piruvato trans-4-Hidroxiprolina SM_Esfingomielina (d18:0,C18:0) Ácido oleico (C18:cis[9]1) Alanina Prolina CER_Ceramida (d18:1,C18:0) Fosfatidilcolina (C18:0,C20:4) Fosfatidilcolina (C16:0,C18:2)
relación
regulación valor p
1,6392
hasta 0,011879
1,572
hasta 4,23E-05
1,5059
hasta 2,41 E-05
1,4663
hasta 0,00067
1,4275
hasta 0,000482
1,3706
hasta 0,002652
1,3664
hasta 0,020521
1,3518
hasta 0,003772
1,3335
hasta 0,004867
1,332
hasta 0,000468
1,3115
hasta 0,001439
1,2874
hasta 0,005757
1,2253
hasta 0,029368
1,187
hasta 0,021168
1,1837
hasta 0,035226
1,1628
hasta 0,001332
1,1575
hasta 0,013187
1,1554
hasta 0,020581
1,0451
hasta 0,001529
1,0142
hasta 0,017665
Tabla 3A.2: Metabolitos que están significativamente disminuidos en plasma (valor p < 0,05) entre pacientes de CHF (ICMP) asintomáticos con NYHA I y controles
METABOLITO CE_Colesterilester C12:0 CE_Colesterilester C20:1 CE_Colesterilester C18:0 Esfingosina-1-fosfato (d17:1) eritro-C16-Esfingosina SM_Esfingomielina (d18:2,C23:1) 5-O-Metilesfiingosina (*1) CE_Colesterilester C20:2 Esfingadienina-1-fosfato (d18:2) 3-O-Metilesfiingosina (*1) Esfingosina-1-fosfato (d18:1) treo-Esfingosina (*1) SM_Esfingomielina (d18:2,C24:2) SM_Esfingomielina (d18:2,C14:0) SM-Esfingomielina (d18:1,C23:1) eritro-Esfingosina (*1) SM_Esfingomielina (d18:1,C24:2) Esfinganina-1-fosfato (d18:0) Fitoesfingosina, total SM_Esfingomielina (d18:1,C16:0) SM-Esfingomielina (d16:1,C24:1) SM_Esfingomielina (d16:1,C16:0) CE_Colesterilester C16:0 Lisofosfatidiletanolamina (C22:5) SM_Esfingomielina (d18:2,C21:0) FS_Colesterol, libre SM_Esfingomielina (d18:2,C24:1)
relación
regulación valor p
0,6027
hasta 0,00105
0,7369
hasta 0,00017
0,7737
hasta 0,00143
0,803
hasta 0,00025
0,8147
hasta 0,00311
0,8247
hasta 0,00017
0,8249
hasta 0,00065
0,8323
hasta 0,00076
0,8333
hasta 0,00026
0,8364
hasta 0,00203
0,8409
hasta 0,00118
0,8433
hasta 0,00014
0,8439
hasta 0,00035
0,8444
hasta 0,00223
0,8516
hasta 0,00045
0,8604
hasta 0,0016
0,8659
hasta 0,00206
0,8684
hasta 0,01946
0,8783
hasta 0,01206
0,8816
hasta 0,00039
0,8836
hasta 0,01867
0,8877
hasta 0,01607
0,8917
hasta 0,01189
0,8927
hasta 0,02336
0,8977
hasta 0,0347
0,8988
hasta 0,02029
0,9026
hasta 0,04993
20
imagen19
imagen20
imagen21
imagen22
(continuación)
METABOLITO
relación regulación valor p
ácido 8-hidroxieicosatetraenoico (C20:[5] trans[9,11,14]4) 1,2893
hasta 0,01092
(8-HETE) TAG (C18:2,C18:2) TAG (C16:0,C18:1,C18:3) N,N-Dimetilarginina (ADMA) Ácido ribónico Esfingosina (d18:1) Carnitina CER_Ceramida (d18:1,C18:0) trans-4-Hidroxiprolina Eritrol Ácido úrico Ácido 14,15-Dihidroxieicosatrienoico (C20:cis[5,8,11]3) DAG (C18:1,C18:2) Ácido 13-hidroxioctadecadienoico (13-HODE) (C18:cis[9] trans[11]2) Creatina Ácido 5-Hidroxi-3-indolacético (5-HIAA) Cistina Ornitina Pseudouridina Homoserina CER_Ceramida (d18:1,C20:0) CER_Ceramida (d18:1,C16:0) Glicerol-3-fosfato, fracción polar Prolina Pentosas mio-Inositol Tirosina Citrato Isoleucina Hexadecanol 5-Oxoprolina CER_Ceramida (d18:1,C24:1) Fenilalanina Sarcosina Fumarato Fosfatidilcolina (C18:0,C18:2)
1,2887
hasta 0,015905
1,279
hasta 0,022255
1,275
hasta 0,003233
1,2754
hasta 7,31E-05
1,2619
hasta 0,04417
1,256
hasta 0,030164
1,2549
hasta 0,000174
1,2455
hasta 0,015447
1,2236
hasta 0,000267
1,2131
hasta 6,69E-05
1,2078
hasta 0,017081
1,2042
hasta 0,034391
1,1878
hasta 0,035187
1,1854
hasta 0,030902
1,1786
hasta 0,025837
1,1522
hasta 0,026543
1,1476
hasta 0,001497
1,1458
hasta 0,000741
1,1422
hasta 0,021709
1,1392
hasta 0,02812
1,1368
hasta 0,001467
1,1367
hasta 0,047191
1,1351
hasta 0,026886
1,1339
hasta 0,017548
1,1268
hasta 0,006009
1,114
hasta 0,010745
1,1116
hasta 0,028918
1,1112
hasta 0,0105
1,1103
hasta 0,046868
1,1092
hasta 0,000298
1,1009
hasta 0,046187
1,0919
hasta 0,005826
1,0863
hasta 0,009006
1,0795
hasta 0,004964
1,011
hasta 0,033217
Tabla 6A.2: Metabolitos que están significativamente disminuidos en plasma (valor p < 0,05) en pacientes de DCPM sintomáticos con NYHA II o NYHA III frente a controles
METABOLITO Sulfato de deshidroepiandrosterona SM_Esfingomielina (d17:1,C23:0) SM_Esfingomielina (d16:1,C24:0) CE_Colesterilester C20:5 Ácido hipúrico SM_Esfingomielina (d16:1,C23:0) CE_Colesterilester C15:0 CE_Colesterilester C14:1 SM_Esfingomielina (d17:1,C24:0) eritro-C16-Esfingosina Colesterilester C18:2 CER_Ceramida (d17:1,C23:0) 1-Hidroxi-2-amino-(cis,trans)-3,5-octadecadieno (*1) SM_Esfingomielina (d16:1,C22:0) Ácido eicosapentaenoico (C20:cis[5,8,11,14,17]5) CE_Colesterilester C12:0 CER_Ceramida (d16:1,C23:0) CER_Ceramida (d17:1,C24:0) CER_Ceramida (d16:1,C24:0) SM_Esfingomielina (d17:1,C22:0) Ácido tricosanoico (C23:0)
relación
regulación valor p
0,5178
hasta 6,03E-05
0,5651
hasta 5,24E-13
0,603
hasta 4,96E-10
0,6079
hasta 6,3E-06
0,6092
hasta 0,004051
0,6162
hasta 4,31 E-14
0,6334
hasta 3,38E-10
0,6428
hasta 0,00125
0,6433
hasta 5,96E-16
0,6456
hasta 2,33E-10
0,6644
hasta 1,01E-09
0,6651
hasta 2,96E-07
0,6659
hasta 9,04E-12
0,6678
hasta 1,17E-11
0,6684
hasta 0,000223
0,6723
hasta 0,007976
0,6728
hasta 3,18E-06
0,6742
hasta 7,34E-08
0,6754
hasta 1,48E-06
0,6766
hasta 6,68E-14
0,6836
hasta 5,19E-12
25
imagen23
imagen24
imagen25
imagen26
Tabla 8A.1: Metabolitos que están significativamente aumentados en plasma (valor p < 0,05) en pacientes de HCMP
sintomáticos con NYHA II o NYHA III frente a controles
METABOLITO Maltosa Sacarosa ácido 12-hidroxieicosatetraenoico (C20:cis[5,8,10,14]4) Sorbitol Esfingadienina (d18:2) Glicerol, fracción lipídica Ácido láurico (C12:0) Fructosa Piruvato Ácido palmitoleico (C16:cis[9]1) Esfingosina (d16:1) SM_Esfingomielina (d18:0,C18:0) TAG (C16:0,C16:1) Ácido oleico (C18:cis[9]1) Noradrenalina (norepinefrina) Ácido heptadecenoico (C17:cis[10]1) Taurina Cistina Ácido palmítico (C16:0) TAG (C16:0,C18:2) CER_Ceramida (d18:1,C18:0) Ácido úrico Ácido eicosenoico (C20:cis[11]1) N,N-Dimetilarginina (ADMA) 2-Hidroxibutirato Ácido esteárico (C18:0) CER_Ceramida (d18:2,C18:0) ácido araquidónico (C20:cis[5,8,11,14]4) SM_Esfingomielina (d18:1,C24:1) eritro-Dihidroesfingosina Glicerolfosfato, fracción lipídica Ácido ribónico Ácido --dihomo-gamma-linoleico (C20:cis[8,11,14]3) isocitrato Eritrol Cisteína Urea CER_Ceramida (d18:1,C24:1) Ácido nervónico (C24:cis[15]1) Arginina CER_Ceramida (d18:1,C16:0) SM_Esfingomielina (d18:1,C18:0) SM_Esfingomielina (d18:2,C18:0) Glucosa-1-fosfato Pseudouridina SM_Esfingomielina (d18:2,C16:0) Glucosa Fosfatidilcolina (C18:0,C20:3) Fosfatidilcolina (C18:0,C20:4)
relación
regulación valor p
1,9048
hasta 4,63E-06
1,6319
hasta 0,005063
1,4659
hasta 0,045714
1,449
hasta 0,018141
1,4046
hasta 0,003857
1,4021
hasta 0,005953
1,4008
hasta 0,046554
1,3913
hasta 0,024517
1,3862
hasta 0,001018
1,3808
hasta 0,004711
1,3506
hasta 0,002776
1,3198
hasta 0,00064
1,2688
hasta 0,04947
1,265
hasta 0,006908
1,2552
hasta 0,01379
1,2412
hasta 0,009838
1,2387
hasta 0,002057
1,2339
hasta 0,003384
1,2333
hasta 0,008969
1,2318
hasta 0,025907
1,2204
hasta 0,003156
1,2023
hasta 0,000657
1,2003
hasta 0,031408
1,193
hasta 0,034953
1,1838
hasta 0,042946
1,1822
hasta 0,010717
1,1778
hasta 0,029595
1,175
hasta 0,006487
1,1695
hasta 0,02742
1,1688
hasta 0,028152
1,1537
hasta 0,044528
1,1534
hasta 0,036068
1,1508
hasta 0,04874
1,1491
hasta 0,010786
1,1465
hasta 0,026373
1,1423
hasta 0,000431
1,1413
hasta 0,045112
1,1373
hasta 0,017432
1,1302
hasta 0,023448
1,1292
hasta 0,03428
1,1208
hasta 0,011296
1,1186
hasta 0,022073
1,117
hasta 0,033572
1,1138
hasta 0,035621
1,1109
hasta 0,019312
1,0871
hasta 0,036787
1,0724
hasta 0,03724
1,0644
hasta 0,021365
1,0411
hasta 0,007723
Tabla 8A.2: Metabolitos que están significativamente disminuidos en plasma (valor p < 0,05) en pacientes de HCPM sintomáticos con NYHA II o NYHA III frente a controles
METABOLITO Biliverdina ácido 12-Hidroxiheptadecatrienoico (C17:[5,8,10]3) Ácido hipúrico Hipoxantina Beta-caroteno Criptoxantina Colesterilester C18:2
relación
regulación valor p
0,460
hasta 0,024536
0,5252
hasta 0,023105
0,6822
hasta 0,033329
0,7217
hasta 0,012505
0,7326
hasta 0,008399
0,7535
hasta 0,031981
0,7662
hasta 0,000292
30
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
Tabla 13B.1: Metabolitos que muestran una correlación significativamente positiva (p < 0,05) con LVEF en plasma de pacientes de CHF y controles
METABOLITO estimación correlación valor p
Ácido hipúrico 1,529516 positivo 2.68E-06
Androstenodiona 1,487558 positivo 3.76E-06
Ácido 7-Metilúrico 1,401171 positivo 8.24E-05
Ácido indol-3-láctico 1,382959 positivo 0,000475
Histidina 1,322863 positivo 1.62E-07
7-Metilxantina 1,322406 positivo 0,000124
O-Acetilcarnitina 1,274541 positivo 0,003596
Carnitina 1,272619 positivo 0,000514
Ácido 1-Metilúrico 1,231272 positivo 0,002592
3,4-Dihidroxifenilalanina (DOPA) 1,205536 positivo 7,71 E-07
Glicina 1,205223 positivo 4.08E-06
Citrato 1,197805 positivo 0,00045
Ácido úrico 1,196162 positivo 0,001527
Ácido pantoténico 1,188484 positivo 0,000115
Metixantina 1,171143 positivo 0,006775
Treonina 1,162344 positivo 8.37E-06
Lisina 1,161343 positivo 0,003507
Ácido 3-hidroxiisovalérico 1,159363 positivo 8.58E-05
Uracilo 1,156814 positivo 1,63E-06
21-Hidroxiprogesterona (11-
Desoxicorticoesterona) 1,1557 positivo 0,007924
Tabla 13B.2: Metabolitos que muestran una correlación significativamente negativa (p < 0,05) con LVEF en plasma de pacientes de CHF y controles
METABOLITO estimación correlación valor p
Furoilglicina Ácido trans-ferúlico
0,687448 0,76225 negativo negativo 0,000503 0,000699
Sacarosa
0,762679 negativo 9.07E-07
Monofosfato
de guanosina cí clico
(GMPc)
0,797882 negativo 1.47E-10
Fructosa
0,840587 negativo 0,002537
Glicerol-3-fosfato, fracción polar
0,850218 negativo 7.94E-05
Normetanefrina
0,866303 negativo 4.53E-08

Tabla 14: Propiedades químicas/físicas de los analitos seleccionados. Estos biomarcadores se caracterizan en el presente documento por las propiedades químicas y físicas.
Metabolito
Modelo de fragmentación (GC-MS) y descripción
Glicerolfosfato, fracción lipídica
Glicerolfosfato, la fracción lipídica representa el parámetro sumatorio de metabolitos que contienen un resto glicerol-2-fosfato o un resto glicerol-3-fosfato y que están presentes en la fracción lipídica tras la extracción y separación del extracto en una fracción polar y una fracción lipídica.
3-O-Metilesfingosina
3-O-Metilesfingosina presenta los siguientes fragmentos iónicos característicos si se detecta con GC/MS, aplicando la espectrometría de masas mediante ionización por impacto de electrones (EI), tras la metanolisis ácida y la derivatización con clorhidrato de O-metilhidroxilamina al 2% en piridina y posteriormente con N-metil-Ntrimetilsililtrifluoracetamida: MS (EI, 70 eV): m/z (%): 204 (100), 73 (18), 205 (16), 206 (7), 354 (4), 442 (1).
5-O-Metilesfingosina
5-O-Metilesfingosina presenta los siguientes fragmentos iónicos característicos si se detecta con GC/MS, aplicando la espectrometría de masas mediante ionización por impacto de electrones (EI), tras la metanolisis ácida y la derivatización con clorhidrato de O-metilhidroxilamina al 2% en piridina y posteriormente con N-metil-Ntrimetilsililtrifluoracetamida: MS (EI, 70 eV): m/z (%): 250 (100), 73 (34), 251 (19), 354 (14), 355 (4), 442 (1).
Deshidroepiandrosterona sulfato
Sulfato de deshidroepiandrosterona representa el parámetro sumatorio de los sulfatos esteroides. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas negativamente es 367,4 (+/-0,5).
58
(continuación)
Metabolito
Modelo de fragmentación (GC-MS) y descripción
Fosfatidilcolina N.º 02
Fosfatidilcolina N.º 02 representa el parámetro sumatorio de las fosfatidilcolinas. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 808,4 (+/-0,5).
TAG (C16:0,C16:1)
TAG (C16:0,C16:1) representa el parámetro sumatorio de los triacilglicéridos que contienen la combinación de una unidad de ácido graso C16:0 y una unidad de ácido graso C16:1. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 549,6 (+/-0,5).
TAG (C16:0,C18:2)
TAG (C16:0,C18:2) representa el parámetro sumatorio de los triacilglicéridos que contienen la combinación de una unidad de ácido graso C16:0 y una unidad de ácido graso C18:2. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 575,6 (+/-0,5).
TAG (C18:1,C18:2)
TAG (C18:1,C18:2) representa el parámetro sumatorio de los triacilglicéridos que contienen la combinación de una unidad de ácido graso C18:1 y una unidad de ácido graso C18:2. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 601,6 (+/-0,5).
TAG (C18:2,C18:2)
TAG (C18:2,C18:2) representa el parámetro sumatorio de los triacilglicéridos que contienen la combinación de dos unidades de ácido graso C18:2. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 599,6 (+/-0,5).
TAG (C18:2, C18:3)
TAG (C18:2,C18:3) representa el parámetro sumatorio de los triacilglicéridos que contienen la combinación de una unidad de ácido graso C18:2 y una unidad de ácido graso C18:3. Presenta las siguientes especies características cuando se detecta con LC/MS, aplicando espectrometría de masas mediante ionización por electropulverización (ESI): la relación masa a carga (m/z) de las especies iónicas cargadas positivamente es 597,6 (+/-0,5).
59

Claims (1)

  1. imagen1
    imagen2
ES12745444.5T 2011-07-28 2012-07-27 Medios y procedimientos para diagnosticar y vigilar la insuficiencia cardiaca en un sujeto Active ES2627019T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161512500P 2011-07-28 2011-07-28
US201161512500P 2011-07-28
EP11175879 2011-07-28
EP11175879 2011-07-28
PCT/EP2012/064823 WO2013014286A2 (en) 2011-07-28 2012-07-27 Means and methods for diagnosing and monitoring heart failure in a subject

Publications (1)

Publication Number Publication Date
ES2627019T3 true ES2627019T3 (es) 2017-07-26

Family

ID=47601593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12745444.5T Active ES2627019T3 (es) 2011-07-28 2012-07-27 Medios y procedimientos para diagnosticar y vigilar la insuficiencia cardiaca en un sujeto

Country Status (8)

Country Link
US (1) US10436798B2 (es)
EP (3) EP2737321B1 (es)
JP (2) JP6185464B2 (es)
AU (2) AU2012288742B2 (es)
CA (1) CA2841915A1 (es)
ES (1) ES2627019T3 (es)
IL (1) IL230492A0 (es)
WO (1) WO2013014286A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9285378B2 (en) * 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
DE102012209059B4 (de) 2012-05-30 2024-05-02 Siemens Healthineers Ag Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet
EP3039430A1 (en) * 2013-08-30 2016-07-06 metanomics GmbH Means and methods for diagnosing heart failure in a subject
US20150090010A1 (en) * 2013-09-27 2015-04-02 Chang Gung University Method for diagnosing heart failure
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
US20170212135A1 (en) * 2014-07-28 2017-07-27 Metanomics Gmbh Means and methods for diagnosing heart failure on the basis of cholesterol parameters, sphingomyelins and/or triacylglycerols
JP2017525970A (ja) * 2014-09-01 2017-09-07 メタノミクス ゲーエムベーハー 被験体において心不全を診断するための手段及び方法
WO2016100549A2 (en) 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
US20180238914A1 (en) * 2015-08-19 2018-08-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
CA3013316A1 (en) 2016-02-04 2017-08-10 Metanomics Gmbh Means and methods for differentiating between heart failure and pulmonary disease in a subject
CN105758966B (zh) * 2016-03-24 2017-12-05 中国药科大学 一组用于诊断冠心病的代谢标志物群
WO2018016645A1 (ja) * 2016-07-22 2018-01-25 国立大学法人秋田大学 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
CN111830142A (zh) * 2019-04-23 2020-10-27 北京市心肺血管疾病研究所 神经酰胺在制备用于评估心力衰竭患者发生不良事件风险的试剂盒中的应用
CN110954606B (zh) * 2019-10-08 2021-04-30 华中科技大学同济医学院附属协和医院 用于诊断结核性胸膜炎的胸水代谢物组合、试剂盒及方法
EP4043884A1 (en) * 2021-02-10 2022-08-17 Eberhard-Karls-Universität Tübingen Medium-chain fatty acyls and phospholipids as biomarkers for cardiovascular diseases
CN115701540A (zh) * 2021-08-02 2023-02-10 中国科学院深圳先进技术研究院 一种用于评估精神分裂症患者心脏损伤的标志物、检测方法和试剂盒
CN115327129A (zh) * 2022-07-05 2022-11-11 上海交通大学医学院附属上海儿童医学中心 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用
CN115181799B (zh) * 2022-09-13 2023-02-03 中国中医科学院医学实验中心 用于预测、检测或诊断心力衰竭的标志物的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
DE19815128A1 (de) 1997-04-03 1998-10-08 Franz Wolfgang M Dr Transgenes Tiermodell für humane Kardiomyopathien
ATE489633T1 (de) 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
DE19915485A1 (de) 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
WO2003073464A1 (de) 2002-02-28 2003-09-04 Metanomics Gmbh & Co. Kgaa Massenspektrometrisches verfahren zur analyse von substanzgemischen
US20080261317A1 (en) * 2004-09-07 2008-10-23 Fifer Michael A Methods of Detecting Myocardial Ischemia and Myocardial Infarction
CA2609728A1 (en) 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
JP4693563B2 (ja) * 2005-09-16 2011-06-01 東ソー株式会社 心不全症候群の識別方法
WO2007072564A1 (ja) 2005-12-22 2007-06-28 Japan Health Sciences Foundation 心不全の治療・予防薬
DE102007010834A1 (de) 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
MX341954B (es) * 2007-07-17 2016-09-08 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros transtornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
US20100267062A1 (en) 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
EP2405806A4 (en) 2009-03-10 2014-01-22 Univ Duke PREDICTION OF CORONARY DISEASE AND THE RISK OF CARDIOVASCULAR EVENTS
US9285378B2 (en) * 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject

Also Published As

Publication number Publication date
EP3527990A1 (en) 2019-08-21
JP6185464B2 (ja) 2017-08-23
EP3190418A1 (en) 2017-07-12
CA2841915A1 (en) 2013-01-31
US10436798B2 (en) 2019-10-08
AU2012288742A1 (en) 2014-01-30
EP2737321A2 (en) 2014-06-04
IL230492A0 (en) 2014-03-31
AU2017201455B2 (en) 2018-08-09
EP3190418B1 (en) 2019-05-01
EP2737321B1 (en) 2017-03-01
AU2012288742B2 (en) 2016-12-08
AU2017201455A1 (en) 2017-03-23
WO2013014286A3 (en) 2013-04-04
JP6495978B2 (ja) 2019-04-03
WO2013014286A2 (en) 2013-01-31
JP2014521949A (ja) 2014-08-28
JP2017223688A (ja) 2017-12-21
US20150160238A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
ES2627019T3 (es) Medios y procedimientos para diagnosticar y vigilar la insuficiencia cardiaca en un sujeto
Berry et al. MALDI imaging MS of phospholipids in the mouse lung [S]
Brouwers Liquid chromatographic–mass spectrometric analysis of phospholipids. Chromatography, ionization and quantification
Peterson et al. A review of chromatographic methods for the assessment of phospholipids in biological samples
Berry et al. Spatial organization of lipids in the human retina and optic nerve by MALDI imaging mass spectrometry [S]
Teo et al. Advances in sample preparation and analytical techniques for lipidomics study of clinical samples
Serna et al. Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry
Deeley et al. Human lens lipids differ markedly from those of commonly used experimental animals
Jackson et al. In situ structural characterization of phosphatidylcholines in brain tissue using MALDI-MS/MS
Sterz et al. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids
Lydic et al. A monophasic extraction strategy for the simultaneous lipidome analysis of polar and nonpolar retina lipids [S]
Yamazaki et al. The proportion of nervonic acid in serum lipids is associated with serum plasmalogen levels and metabolic syndrome
Schuhmann et al. Monitoring membrane lipidome turnover by metabolic 15N labeling and shotgun ultra-high-resolution orbitrap Fourier transform mass spectrometry
Balvers et al. Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in C57BL/6 mice fed a fish-oil diet
Hayasaka et al. Organ-specific distributions of lysophosphatidylcholine and triacylglycerol in mouse embryo
Xie et al. Development and application of a comprehensive lipidomic analysis to investigate Tripterygium wilfordii-induced liver injury
Shimizu et al. Mass spectrometric discrimination of squalene monohydroperoxide isomers
Mori et al. Rapid identification of fatty acids and (O-acyl)-ω-hydroxy fatty acids in human meibum by liquid chromatography/high-resolution mass spectrometry
Garlito et al. Identification of very long-chain (> C24) fatty acid methyl esters using gas chromatography coupled to quadrupole/time-of-flight mass spectrometry with atmospheric pressure chemical ionization source
Shi et al. An in vitro metabolomics approach to identify hepatotoxicity biomarkers in human L02 liver cells treated with pekinenal, a natural compound
JP2018517890A (ja) 皮膚リピドミックアッセイ
JP2018508774A (ja) 非アルコール性脂肪性肝疾患を特定するための方法及び組成物
Nagy et al. Mapping the regioisomeric distribution of fatty acids in triacylglycerols by hybrid mass spectrometry [S]
Nagy et al. Comparative study of serine-plasmalogens in human retina and optic nerve: identification of atypical species with odd carbon chains
Beermann et al. sn‐Position determination of phospholipid‐linked fatty acids derived from erythrocytes by liquid chromatography electrospray ionization ion‐trap mass spectrometry